Journal of the American Academy of Dermatology
Volume 55, Issue 3 , Pages 369-389 , September 2006

Azathioprine in dermatology: The past, the present, and the future

References 

  1. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci. 1993;685:400–407
  2. Rundles RW, Laszlo J, Itoga T, Hobson JB, Garrison FE. Clinical and hematologic study of 6-[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W. 57-322) and related compounds. Cancer Chemother Rep. 1961;14:99–115
  3. Moschella SL. The present status of chemotherapy in dermatology. Med Clin North Am. 1972;56:725–737
  4. Ashton H, Beveridge GW, Stevenson CJ. Therapeutics. XI. Immunosuppressive drugs. Br J Dermatol. 1970;83:326–330
  5. Rosman M, Bertino JR. Azathioprine. Ann Intern Med. 1973;79:694–700
  6. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics. 1999;15:317–337
  7. Tan BB, Lear JT, Gawkrodger DJ, English JS. Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol. 1997;136:351–355
  8. Medawar PB. Immunological tolerance. Science. 1961;133:303–306
  9. Billingham RE, Brent L, Medawar PB. Acquired tolerance of skin homografts. Ann N Y Acad Sci. 1955;59:409–416
  10. Elion GB, Hitchings GH, Vanderwerff H. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem. 1951;192:505–518
  11. Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Ann N Y Acad Sci. 1954;60:195–199
  12. Elion GB. The purine path to chemotherapy. Science. 1989;244:41–47
  13. Hitchings GH, Elion GB. Chemical suppression of the immune response. Pharmacol Rev. 1963;15:365–405
  14. Porter KA, Murray JE. Homologous marrow transplantation in rabbits after triethylenethiophosphoramide. Arch Surg. 1958;76:908–911
  15. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature. 1959;183:1682–1683
  16. Calne RY. The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet. 1960;1:417–418
  17. Calne RY. The initial study of the immunosuppressive effects of 6-mercaptopurine and azathioprine in organ transplantation and a few words on cyclosporin A. World J Surg. 1982;6:637–640
  18. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull. 1961;28:65–81
  19. Calne RY, Murray JE. Inhibition of the rejection of renal homografts in dogs by Burroughs Wellcome 57-322. Surg Forum. 1961;12:118–120
  20. Elion GB, Callahan SW, Bieber S, Hitchings GH, Rundles RW. A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W. 57-322). Cancer Chemother Rep. 1961;14:93–98
  21. Dameshek W, Schwartz R. Treatment of certain “autoimmune” diseases with antimetabolites; a preliminary report. Trans Assoc Am Phys. 1960;73:113–127
  22. Corley CC, Lessner HE, Larsen WE. Azathioprine therapy of “autoimmune” diseases. Am J Med. 1966;41:404–412
  23. Wolff K, Schreiner E. [Immunosuppressive therapy of pemphigus vulgaris. Preliminary results of azathioprine [Imuran] treatment)]. Arch Klin Exper Dermatol. 1969;235:63–77
  24. Krakowski A, Covo J, Rozanski Z. Pemphigus vulgaris. Arch Dermatol. 1969;100:117
  25. Belgi G, Friedmann PS. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Clin Exper Dermatol. 2002;27:546–554
  26. Elion GB. Significance of azathioprine metabolites. Proc Roy Soc Med. 1972;65:257–260
  27. de Miranda P, Beacham LM, Creagh TH, Elion GB. The metabolic disposition of 14C-azathioprine in the dog. J Pharmacol Exper Ther. 1975;195:50–57
  28. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–339
  29. Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol Sci. 1997;18:3–7
  30. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 2001;61:5810–5816
  31. Sauer H, Hantke U, Wilmanns W. Azathioprine lymphocytotoxicity. Potentially lethal damage by its imidazole derivatives. Arzneimittelforschung. 1988;38:820–824
  32. Hoffmann M, Rychlewski J, Chrzanowska M, Hermann T. Mechanism of activation of an immunosuppressive drug: azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine. J Am Chem Soc. 2001;123:6404–6409
  33. Nyhan WL. The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J Inherit Metab Dis. 1997;20:171–178
  34. Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency in the Lesch-Nyhan syndrome and gout. Fed Proc. 1968;27:1047–1052
  35. Bertino JR. Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man. Arthritis Rheum. 1973;16:79–83
  36. Elion GB. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc. 1967;26:898–904
  37. Clarke DA, Elion GB, Hitchings GH, Stock CC. Structure-activity relationships among purines related to 6-mercaptopurine. Cancer Res. 1958;18:445–456
  38. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738–746
  39. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122–1124
  40. Hurd ER. Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis Rheum. 1973;16:84–88
  41. Gassmann AE, van Furth R. The effect of azathioprine (Imuran) on the kinetics of monocytes and macrophages during the normal steady state and an acute inflammatory reaction. Blood. 1975;46:51–64
  42. Levy J, Barnett EV, MacDonald NS, Klinenberg JR, Pearson CM. The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest. 1972;51:2233–2238
  43. Baadsgaard O. Circulating and in situ lymphocyte subsets and Langerhans cells in patients with compositae oleoresin dermatitis and increased ultraviolet A sensitivity during treatment with azathioprine. J Am Acad Dermatol. 1986;14:577–581
  44. Halliday GM, Knight BA, Muller HK. Reduction in murine Langerhans cell ATPase staining following topical but not systemic treatment with steroid and non-steroid immunosuppressants. Br J Dermatol. 1986;114:83–89
  45. Bergfelt L, Larko O, Blohme I. Skin disease in immunosuppressed patients in relation to epidermal Langerhans' cells. Acta Derm Venereol Suppl (Stockh). 1993;73:330–334
  46. Gilhar A, Enat R, Baruch Y. HLA-DR positive epidermal Langerhans' cells in liver cirrhosis and immunosuppressed liver transplanted patients. Acta Derm Venereol Suppl (Stockh). 1994;74:93–94
  47. Liu HN, Wong CK. In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res. 1997;289:94–97
  48. Gorski A, Korczak-Kowalska G, Nowaczyk M, Paczek L, Gaciong Z. The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology. 1983;6:259–266
  49. Fournier C, Bach MA, Dardenne M, Bach JF. Selective action of azathioprine on T cells. Transpl Proc. 1973;5:523–526
  50. Galanaud P, Crevon MC, Erard D, Wallon C, Dormont J. Two processes for B-cell triggering by T-independent antigens as evidenced by the effect of azathioprine. Cell Immunol. 1976;22:83–92
  51. Voogd CE. Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutat Res. 1989;221:133–152
  52. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133–1145
  53. Dalke AP, Kazmers IS, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase-independent toxicity of azathioprine in human lymphoblasts. Biochem Pharmacol. 1984;33:2692–2695
  54. Szawlowski PW, Al-Safi SA, Dooley T, Maddocks JL. Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome. Br J Clin Pharmacol. 1985;20:489–491
  55. Crawford DJ, Maddocks JL, Jones DN, Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem. 1996;39:2690–2695
  56. Aarbakke J. Biology and pharmacology of thiopurines. Pediatr Hematol Oncol. 1995;12:511–519
  57. Evans WE. Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics. 2002;12:421–423
  58. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46:149–154
  59. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429–436
  60. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996;15:17–30
  61. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet. 2000;45:299–302
  62. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–662
  63. Vuchetich JP, Weinshilboum RM, Price RA. Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genet Epidemiol. 1995;12:1–11
  64. Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey AV. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM. 2002;95:439–444
  65. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978;85:323–333
  66. Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol. 1998;54:265–271
  67. Menor C, Fueyo JA, Escribano O, Cara C, Fernandez-Moreno MD, Roman ID, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit. 2001;23:536–541
  68. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet. 1982;20:637–658
  69. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85:1897–1902
  70. Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exper Ther. 1982;222:174–181
  71. Szumlanski CL, Scott MC, Weinshilboum RM. Thiopurine methyltransferase (TPMT) pharmacogenetics: human liver enzyme activity. Clin Pharmacol Ther. 1988;43:134
  72. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992;2:148–159
  73. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol. 2002;37:441–447
  74. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol. 2001;57:51–54
  75. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193–197
  76. Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol. 1997;136:133–134
  77. Tavadia SM, Mydlarski PR, Reis MD, Mittmann N, Pinderton PH, Shear N, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol. 2000;42:628–632
  78. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol. 2002;29:2507–2512
  79. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogen J. 2001;1:254–261
  80. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89–98
  81. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994;55:15–20
  82. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37–42
  83. Tsironi E, Browne M, Rampton DS, Ballinger AB. Expression of thiopurine methyltransferase in South Asians. Gut. 2003;52:914–915
  84. Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH, Aarbakke J. Thiopurine methyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther. 1996;60:68–74
  85. Lowenthal A, Meyerstein N, Ben-Zvi Z. Thiopurine methyltransferase activity in the Jewish population of Israel. Eur J Clin Pharmacol. 2001;57:43–46
  86. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw M, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999;9:773–776
  87. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8:367–370
  88. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560–569
  89. In:  Lebwohl M,  Heymann WR,  Berth-Jones J,  Coulson I editor. Treatment of skin disease. Philadelphia: Mosby; 2002;
  90. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113:1236–1241
  91. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984;120:44–47
  92. Roenigk HH, Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol. 1973;107:353–357
  93. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol. 1990;22:35–40
  94. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol. 1987;16:527–533
  95. Ahmed AR, Salm M. Juvenile pemphigus. J Am Acad Dermatol. 1983;8:799–807
  96. Lam S, Stone MS, Goeken JA, Massicotte SJ, Smith AC, Folberg R, et al. Paraneoplastic pemphigus, cicatricial conjunctivitis, and acanthosis nigricans with pachydermatoglyphy in a patient with bronchogenic squamous cell carcinoma. Ophthalmology. 1992;99:108–113
  97. Lynde CW, Ongley RC, Rigg JM. Juvenile pemphigus vulgaris. Arch Dermatol. 1984;120:1098–1099
  98. Mourellou O, Chaidemenos GC, Koussidou T, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol. 1995;133:83–87
  99. Walker AE. Pemphigus vulgaris. Br J Dermatol. 1978;99(Suppl 16):60
  100. Fine JD, Appell ML, Green LK, Sams WM. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988;124:236–239
  101. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140:84–89
  102. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34:645–652
  103. Verrini A, Cannata G, Cozzani E, Terracini M, Parodi A, Rebora A. A patient with immunological features of paraneoplastic pemphigus in the absence of a detectable malignancy. Acta Derm Venereol Suppl (Stockh). 2002;82:382–384
  104. van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973;147:179–185
  105. van Vloten WA. Pemphigus foliaceus. Dermatologica. 1972;144:356
  106. Harangi F, Varszegi D, Schneider I, Zombai E. Complete recovery from juvenile pemphigus vulgaris. Pediatr Dermatol. 2001;18:51–53
  107. Wananukul S, Pongprasit P. Childhood pemphigus. Int J Dermatol. 1999;38:29–35
  108. Ljubojevic S, Lipozencic J, Brenner S, Budimcic D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002;16:599–603
  109. Burton JL, Greaves MW, Marks J, Dawber RP. Azathioprine in pemphigus vulgaris. Br Med J. 1970;3:84–86
  110. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol. 1970;83:315–323
  111. Charow A, Pass F, Ruben R. Pemphigus of the upper respiratory tract. Arch Otolaryngol. 1971;93:209–210
  112. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113:1043–1046
  113. Dantzig P. Circulating antibodies in cicatricial pemphigoid. Arch Dermatol. 1973;108:264–266
  114. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26:585–589
  115. Warren SD, Lesher JL. Cicatricial pemphigoid. South Med J. 1993;86:461–464
  116. Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129:49–53
  117. Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol. 1974;90:183–186
  118. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a 4 year follow-up. Br J Dermatol. 1974;91:103–109
  119. Burton JL, Harman RM, Peachey RD, Warin RP. A controlled trial of azathioprine in the treatment of pemphigoid. Br J Dermatol. 1978;99(Suppl 16):14
  120. Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2:1190–1191
  121. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983;96:453–459
  122. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991;10:185–195
  123. Roeder C, Driesch PV. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9:537–539
  124. Pawlofsky C, Simon M, Fartasch M, Keller J. Disseminated cicatricial pemphigoid. Dermatologica. 1985;171:259–263
  125. Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971;1:144–145
  126. Anstey A. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129:1203–1204
  127. Callen JP. Immunosuppressive and cytotoxic drugs: uses in the dermatologic patient. Adv Dermatol. 1990;5:3–19discussion, 20
  128. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exper Med Biol. 1999;455:343–348
  129. Hacker SM, Ramos-Caro FA, Ford MJ, Flowers FP. Azathioprine: a forgotten alternative for treatment of severe psoriasis. Int J Dermatol. 1992;31:873–874
  130. Munro DD. Azathioprine in psoriasis. Proc R Soc Med. 1973;66:747–748
  131. Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J. 1974;1:49–51
  132. Greaves MW, Dawber R. Azathioprine in psoriasis. Br Med J. 1970;2:237–238
  133. Primka EJ, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol. 1998;39:121–123
  134. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147:324–330
  135. Morrison JG, Schulz EJ. Treatment of eczema with cyclophosphamide and azathioprine. Br J Dermatol. 1978;98:203–207
  136. Younger IR, Harris DW, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol. 1991;25:281–286
  137. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exper Dermatol. 2001;26:369–375
  138. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol. 2002;43:125–127
  139. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol. 1998;11:137–140
  140. Lear JT, English JS, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol. 1996;35:642–643
  141. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147:308–315
  142. Verma KK, Manchanda Y, Pasricha JS. Azathioprine as a corticosteroid sparing agent for the treatment of dermatitis caused by the weed Parthenium. Acta Derm Venereol Suppl (Stockh). 2000;80:31–32
  143. Sharma VK, Chakrabarti A, Mahajan V. Azathioprine in the treatment of Parthenium dermatitis. Int J Dermatol. 1998;37:299–302
  144. Roelandts R. Chronic actinic dermatitis. J Am Acad Dermatol. 1993;28:240–249
  145. Kingston TP, Lowe NJ, Sofen HL, Weingarten DP. Actinic reticuloid in a black man: successful therapy with azathioprine. J Am Acad Dermatol. 1987;16:1079–1083
  146. Roed-Petersen J, Thomsen K. Azathioprin in the treatment of airborne contact dermatitis from compositae oleoresins and sensitivity to UVA. Acta Derm Venereol Suppl (Stockh). 1980;60:275–277
  147. Haynes HA, Bernhard JD, Gange RW. Actinic reticuloid. Response to combination treatment with azathioprine, hydroxychloroquine, and prednisone. J Am Acad Dermatol. 1984;10:947–952
  148. Lim HW, Morison WL, Kamide R, Buchness MR, Harris R, Soter NA. Chronic actinic dermatitis. An analysis of 51 patients evaluated in the United States and Japan. Arch Dermatol. 1994;130:1284–1289
  149. Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol. 1984;110:691–695
  150. Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989;121:639–646
  151. Dawe RS, Ferguson J. Diagnosis and treatment of chronic actinic dermatitis. Dermatol Ther. 2003;16:45–51
  152. Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol. 1989;125:1377–1379
  153. Nethercott J, Lester RS. Azathioprine therapy in incomplete Behcet syndrome. Arch Dermatol. 1974;110:432–434
  154. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281–285
  155. Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87:42–45
  156. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol. 1993;128:542–545
  157. Pavlovic MD, Karadaglic DM, Kandolf LO, Mijuskovic ZP. Persistent erythema multiforme: a report of three cases. J Eur Acad Dermatol Venereol. 2001;15:54–58
  158. Jones RR. Azathioprine therapy in the management of persistent erythema multiforme. Br J Dermatol. 1981;105:465–467
  159. Klein LR, Callen JP. Azathioprine: effective steroid-sparing therapy for generalized lichen planus. South Med J. 1992;85:198–201
  160. Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exper Dermatol. 1996;21:56–57
  161. Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol Suppl (Stockh). 2001;81:378–379
  162. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med. 1991;151:2249–2254
  163. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127:515–522
  164. Pickering JG. Wegener's granuloma treated with azathioprine. Proc R Soc Med. 1972;65:592–593
  165. Thomas RH, Black MM. The wide clinical spectrum of polyarteritis nodosa with cutaneous involvement. Clin Exper Dermatol. 1983;8:47–59
  166. Hafeez ZH. Unusual presentation of cutaneous vasculitis. Int J Dermatol. 1998;37:687–690
  167. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervert JWC, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44
  168. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol. 1985;121:1323–1325
  169. Ashinoff R, Werth VP, Franks AG. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol. 1988;19:961–965
  170. Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol. 1986;122:376–377
  171. Calin A. A placebo controlled, crossover study of azathioprine in Reiter's syndrome. Ann Rheum Dis. 1986;45:653–655
  172. Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138:924–934
  173. Gaziev D, Lucarelli G, Polchi P, Angelucci E, Galimberti M, Giardini C, et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. Bone Marrow Transplant. 2001;27:45–51
  174. Lear JT, English JS, Smith AG. Nodular prurigo responsive to azathioprine. Br J Dermatol. 1996;134:1151
  175. Freeman K, Hewitt M, Warin AP. Two cases of distinctive exudative discoid and lichenoid chronic dermatosis of Sulzberger and Garbe responding to azathioprine. Br J Dermatol. 1984;111:215–220
  176. Woolfson H. Acne fulminans with circulating immune complexes and leukaemoid reaction treated with steroids and azathioprine. Clin Exper Dermatol. 1987;12:463–466
  177. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769–774
  178. Callen JP. Immunosuppressive and cytotoxic drugs in the treatment of rheumatic skin disorders. Semin Cutan Med Surg. 2001;20:58–68
  179. Shih YL, Chang DM. Excellent effect of steroid plus azathioprine in a young woman with pernicious anaemia and systemic lupus erythematosus. Clin Rheumatol. 2000;19:492–494
  180. Swaak AJ, Statius van Eps LW, Aarden LA, Feltkamp TE. Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study. Clin Rheumatol. 1984;3:285–291
  181. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18:27–34
  182. Jacobs JC. Treatment of systemic lupus erythematosus in childhood. Arthritis Rheum. 1977;20(suppl):304–307
  183. Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971;14:639–645
  184. Jansen GT, Barraza DF, Ballard JL, Honeycutt WM, Dillaha CJ. Generalized scleroderma. Treatment with an immunosuppressive agent. Arch Dermatol. 1968;97:690–698
  185. Kurwa AR, Denman AM. Scleroderma treated with immunosuppressive drugs. Br J Dermatol. 1979;101(Suppl 17):56–57
  186. Hamilton EB. Juvenile dermatomyositis. Br J Dermatol. 1976;95(Suppl 14):41–43
  187. Mittal R, Sharma VK, Prasad HR, Singh MK. Mechanic's hand: a clinical diagnostic aid in dermatomyositis. Acta Derm Venereol Suppl (Stockh). 2001;81:65–66
  188. Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59:212–218
  189. Silvis NG. Antimetabolites and cytotoxic drugs. Dermatol Clin. 2001;19:105–118viii–ix
  190. Badalamenti S, Kerdel FA. Azathioprine. In:  Wolverton SE editors. Comprehensive dermatologic drug therapy. Philadelphia: Saunders; 2001;p. 165–179
  191. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol. 1992;28:148–152
  192. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115:1100–1106
  193. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160:610–619
  194. Marushak A, Weber T, Bock J, Birkeland SA, Hansen HE, Klebe J, et al. Pregnancy following kidney transplantation. Acta Obstet Gynecol Scand. 1986;65:557–559
  195. Farber M, Kennison RD, Jackson HT, Sbarra AJ, Widmere B, Barnes BA. Successful pregnancy renal transplantation. Obstet Gynecol. 1976;48(suppl):2S–4S
  196. Miniero R, Tardivo I, Curtoni ES, Segoloni GP, Rocca EL, Nino A, et al. Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol. 2002;15:626–632
  197. Haagsma EB, Visser GH, Klompmaker IJ, Verwer R, Slooff MJ. Successful pregnancy after orthotopic liver transplantation. Obstet Gynecol. 1989;74:442–443
  198. Sharon E, Jones J, Diamond H, Kaplan D. Pregnancy and azathioprine in systemic lupus erythematosus. Am J Obstet Gynecol. 1974;118:25–28
  199. Gillibrand PN. Systemic lupus erythematosus in pregnancy treated with azathioprine. Proc R Soc Med. 1966;59:834
  200. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99:443–446
  201. Tsanadis GD, Chouliara ST, Voulgari PV, Makrydimas GV, Drosos AA. Outcome of pregnancy in a patient with relapsing polychondritis and pyoderma gangrenosum. Clin Rheumatol. 2002;21:538
  202. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 1995;38:1722–1732
  203. Tendron A, Gouyon JB, Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol. 2002;17:121–130
  204. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol. 1985;92:233–239
  205. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984;105:625–628
  206. Cote CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85:324–328
  207. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981;58:247–250
  208. Gebhardt DO. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1983;61:270
  209. Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology. 2001;121:1048–1053
  210. Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26:99–102
  211. Coulam CB, Moyer TP, Jiang NS, Zincke H. Breast-feeding after renal transplantation. Transplant Proc. 1982;14:605–609
  212. Rayburn WF. Connective tissue disorders and pregnancy. Recommendations for prescribing. J Reprod Med. 1998;43:341–349
  213. Lehrnbecher T, Kontny HU, Jeschke R. Metastatic Crohn's disease in a 9-year-old boy. J Pediatr Gastroenterol Nutr. 1999;28:321–323
  214. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999;28:54–58
  215. Fuentes D, Torrente F, Keady S, Thirrupathy K, Thomson MA, Walker-Smith JA, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:913–921
  216. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990;117:809–814
  217. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev Gastroenterol Disord. 2003;3(Suppl 1):S23–S29
  218. Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomed Pharmacother. 1982;36:217–222
  219. Prager D, Rosman M, Bertino JR. Letter: azathioprine and allopurinol. Ann Intern Med. 1974;80:427
  220. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990;228:69–71
  221. Bernstein LS. The interaction between allopurinol and azathioprine. J Intern Med. 1993;233:426–427
  222. Boyd IW. Allopurinol-azathioprine interaction. J Intern Med. 1991;229:386
  223. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30:951–954
  224. Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. Am J Med. 1992;92:217
  225. Rivier G, Khamashta MA, Hughes GR. Warfarin and azathioprine: a drug interaction does exist. Am J Med. 1993;95:342
  226. Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy. 2001;21:355–357
  227. Walker J, Mendelson H, McClure A, Smith MD. Warfarin and azathioprine: clinically significant drug interaction. J Rheumatol. 2002;29:398–399
  228. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. [erratum appears in Ann Pharmacother 2001;35:1296] Ann Pharmacother. 2000;34:120–122
  229. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther. 2002;16:79–85
  230. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656–664
  231. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456–459
  232. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999;116:1505–1506
  233. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49:393–396
  234. Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1980;93:560–562
  235. Zylber-Katz E, Putterman C, Caraco Y. Multiple drug overdose in a kidney transplant patient. Ther Drug Monit. 1994;16:327–331
  236. Carney DM, Zukoski CF, Ogden DA. Massive azathioprine overdose. Case report and review of the literature. Am J Med. 1974;56:133–136
  237. Assini JF, Hamilton R, Strosberg JM. Adverse reactions to azathioprine mimicking gastroenteritis. J Rheumatol. 1986;13:1117–1118
  238. Lawson DH, Lovatt GE, Gurton CS, Hennings RC. Adverse effects of azathioprine. Adverse Drug React Toxicol Rev. 1984;3:161–171
  239. Jones JJ, Ashworth J. Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol. 1993;29:795–796
  240. Zimmerman SW, Esch J. Skin lesions treated with azathioprine and prednisone. Comparison of nontransplant patients and renal transplant recipients. Arch Intern Med. 1978;138:912–914
  241. McLelland J, Rees A, Williams G, Chu T. The incidence of immunosuppression-related skin disease in long-term transplant patients. Transplantation. 1988;46:871–874
  242. Klein MB, Pereira FA, Kantor I. Kaposi sarcoma complicating systemic lupus erythematosus treated with immunosuppression. Arch Dermatol. 1974;110:602–604
  243. Weiss VC, Serushan M. Kaposi's sarcoma in a patient with dermatomyositis receiving immunosuppressive therapy. Arch Dermatol. 1982;118:183–185
  244. Vandercam B, Lachapelle JM, Janssens P, Tennstedt D, Lambert M. Kaposi's sarcoma during immunosuppressive therapy for atopic dermatitis. Dermatology. 1997;194:180–182
  245. Halpern SM, Parslew R, Cerio R, Kirby JT, Sharpe GR. Kaposi's sarcoma associated with immunosuppression for bullous pemphigoid. Br J Dermatol. 1997;137:140–143
  246. Virgili A, Zampino MR, La Malfa V, Strumia R, Bedani PL. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology. 1999;199:31–34
  247. Burkhart CG, Dvorak N, Stockard H. An unusual case of tinea versicolor in an immunosuppressed patient. Cutis. 1981;27:56–58
  248. Orton DI, Orteu CH, Rustin MH. Cytomegalovirus-associated gastric ulcer in an immunosuppressed patient with pemphigus vulgaris. Clin Exper Dermatol. 2001;26:170–172
  249. Anolik MA, Rudolph RI. Scabies simulating Darier disease in an immunosuppressed host. Arch Dermatol. 1976;112:73–74
  250. Espy PD, Jolly HW. Norwegian scabies: occurrence in a patient undergoing immunosuppression. Arch Dermatol. 1976;112:193–196
  251. Paterson WD, Allen BR, Beveridge GW. Norwegian scabies during immunosuppressive therapy. Br Med J. 1973;4:211–212
  252. Bricklin AS, Musgnug RH. Norwegian scabies. A new complication of immunosuppressive therapy. Cutis. 1978;22:81–84
  253. Soni BP, Sherertz EF. Allergic contact dermatitis from azathioprine. Am J Contact Dermat. 1996;7:116–117
  254. Burden AD, Beck MH. Contact hypersensitivity to azathioprine. Contact Dermat. 1992;27:329–330
  255. Lauerma AI, Koivuluhta M, Alenius H. Recalcitrant allergic contact dermatitis from azathioprine tablets. Contact Dermat. 2001;44:129
  256. Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP. Hypersensitivity reaction to azathioprine. South Med J. 1998;91:471–474
  257. Sinico RA, Sabadini E, Borlandelli S, Cosci P, Di Toma L, Imbasciati E. Azathioprine hypersensitivity: report of two cases and review of the literature. J Nephrol. 2003;16:272–276
  258. Garey KW, Streetman DS, Rainish MC. Azathioprine hypersensitivity reaction in a patient with ulcerative colitis. Ann Pharmacother. 1998;32:425–428
  259. Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions—a case report and a review of the literature. Clin Exper Dermatol. 1995;20:353–356
  260. Saway PA, Heck LW, Bonner JR, Kirklin JK. Azathioprine hypersensitivity. Case report and review of the literature. Am J Med. 1988;84:960–964
  261. Brown G, Boldt C, Webb JG, Halperin L. Azathioprine-induced multisystem organ failure and cardiogenic shock. Pharmacotherapy. 1997;17:815–818
  262. Collison DW, Dahlberg PJ, Hogan JD. Azathioprine hypersensitivity in bullous pemphigoid. J Am Acad Dermatol. 1990;23:125–127
  263. Guillaume P, Grandjean E, Male PJ. Azathioprine-associated acute pancreatitis in the course of chronic active hepatitis. Dig Dis Sci. 1984;29:78–79
  264. Paloyan D, Levin B, Simonowitz D. Azathioprine-associated acute pancreatitis. Am J Dig Dis. 1977;22:839–840
  265. Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis. N Engl J Med. 1973;289:357
  266. Lemley DE, DeLacy LM, Seeff LB, Ishak KG, Nashel DJ. Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann Rheum Dis. 1989;48:342–346
  267. Adler M, Delhaye M, Deprez C, Hardy N, Gelin M, De Pauw L, et al. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Nephrol Dial Transplant. 1987;2:183–188
  268. Liano F, Moreno A, Matesanz R, Teruel JL, Redondo C, Garcia-Martin F, et al. Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause?. Nephron. 1989;51:509–516
  269. Weitz H, Gokel JM, Loeschke K, Possinger K, Eder M. Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Archiv. 1982;395:245–256
  270. Marubbio AT, Danielson B. Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine. Gastroenterology. 1975;69:739–743
  271. Holtmann M, Schreiner O, Kohler H, Denzer U, Neurath M, Galle PR, et al. Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci. 2003;48:1503–1505
  272. Kohli HS, Jain D, Sud K, Jha V, Gupta KL, Sakhuja V, et al. Azathioprine-induced hepatic veno-occlusive disease in a renal transplant recipient: histological regression following azathioprine withdrawal. Nephrol Dial Transplant. 1996;11:1671–1672
  273. Cohen SM, Erturk E, Skibba JL, Bryan GT. Azathioprine induction of lymphomas and squamous cell carcinomas in rats. Cancer Res. 1983;43:2768–2772
  274. Casey TP. Azathioprine (Imuran) administration and the development of malignant lymphomas in NZB mice. Clin Exper Immunol. 1968;3:305–312
  275. Clark JM. The mutagenicity of azathioprine in mice, Drosophila melanogaster and Neurospora crassa. Mutat Res. 1975;28:87–99
  276. Casey TP. The development of lymphomas in mice with autoimmune disorders treated with azathioprine. Blood. 1968;31:396–399
  277. Dalton A, Curtis D, Harrington CI. Synergistic effects of azathioprine and ultraviolet light detected by sister chromatid exchange analysis. Cancer Genet Cytogenet. 1990;45:93–99
  278. Kelly GE, Meikle WD, Moore DE. Enhancement of UV-induced skin carcinogenesis by azathioprine: role of photochemical sensitization. Photochem Photobiol. 1989;49:59–65
  279. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–186
  280. Westburg SP, Stone OJ. Multiple cutaneous squamous cell carcinomas during immunosuppressive therapy. Arch Dermatol. 1973;107:893–895
  281. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol. 1995;133:460–462
  282. Gjersvik P, Hansen S, Moller B, Leivestad T, Geiran O, Simonsen S, et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?. Transplant Int. 2000;13(Suppl 1):S380–S381
  283. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol Suppl (Stockh). 1992;72:115–119
  284. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation. 1996;61:715–721
  285. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249–1252
  286. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16:1225–1232
  287. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738–745
  288. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705–1714
  289. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988;47:988–992
  290. Phillips T, Salisbury J, Leigh I, Baker H. Non-Hodgkin's lymphoma associated with long-term azathioprine therapy. Clin Exper Dermatol. 1987;12:444–445
  291. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46:1607–1612
  292. Lloveras JJ, Cointault O, Huyn A, Boyer M, Fournial G, Rostaing L, et al. Decreased incidence of lymphomas after heart transplantation under low-dose immunosuppression. Transplant Proc. 1995;27:1778
  293. Bunney MH, Benton EC, Barr BB, Smith IW, Anderton JL, Hunter JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant. 1990;5:379–382
  294. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–142

 Funding sources: None.Conflict of interest: None identified.

PII: S0190-9622(05)02384-4

doi: 10.1016/j.jaad.2005.07.059

Journal of the American Academy of Dermatology
Volume 55, Issue 3 , Pages 369-389 , September 2006

Article Tools

* Image Usage & Resolution